-
Product Insights
NewBAG Family Molecular Chaperone Regulator 3 – Drugs In Development, 2024
The BAG Family Molecular Chaperone Regulator 3 pipeline drugs market research report outlays comprehensive information on the BAG Family Molecular Chaperone Regulator 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Central Nervous System, and Oncology which include indications of Dilated Cardiomyopathy, Unspecified Cardiovascular Disorders, Unspecified Central Nervous System Disorders, and Pancreatic Ductal Adenocarcinoma. It also...
-
Product Insights
NewPrecision Molecular Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Precision Molecular Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Precision Molecular Inc (Precision Molecular) is engaged in developing imaging biomarkers and theragnostic. Precision Molecular is headquartered in Gaithersburg, Maryland, the US. GlobalData's Medical Devices company profile report, “Precision Molecular Inc Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data related...
-
Product Insights
NewNeuMoDx Molecular Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our NeuMoDx Molecular Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. NeuMoDx Molecular Inc (NMM), a subsidiary of Qiagen NV, provides a platform that integrates the molecular diagnostic process from sample to result. It develops solutions for clinical reference laboratories and molecular diagnostic testing in hospital. The company is headquartered in Ann Arbor, Michigan, the US. GlobalData's Medical Devices company profile report, “NeuMoDx Molecular Inc Pipeline Insight and Competitive Landscape,...
-
Product Insights
NewLife Molecular Imaging SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Life Molecular Imaging SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Life Molecular Imaging SA (Life Molecular Imaging) a medical equipment company which includes research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. The company is headquartered in Matran, Fribourg, Switzerland. GlobalData's Medical Devices company profile report, “Life Molecular Imaging SA Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on...
-
Product Insights
NewRoche Molecular Systems Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Roche Molecular Systems Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Roche Molecular Systems Inc (RMD) a subsidiary of F. Hoffmann-La Roche Ltd, is developer, manufacturer and supplier of medical diagnostic products and blood screening assays based on its polymerase chain reaction (PCR) technologies. The company offers products such as cobas amplicor analyzer, cobas taqscreen DPX test, cobas s 201 system, cobas taqscreen MPX test, cobas taqscreen MPX test,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AAA-603...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603 in Lung Cancer Drug Details: AAA-603 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603 in Ovarian Cancer Drug Details: AAA-603 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603 in Head And Neck Cancer Drug Details: AAA-603...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-603 in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-603 in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-603 in Gastrointestinal Stromal Tumor (GIST) Drug Details: AAA-603...